News & Updates

Use of ferric carboxymaltose in patients who have heart failure with a reduced ejection fraction and iron deficiency appears to yield only numerical improvements the hierarchical composite of death, hospitalizations for heart failure, or 6-minute walk distance as compared with placebo, according to data from the HEART-FID trial.

Atrial fibrillation (AF) appears to contribute to an increased risk of rapid progresssion to mild cognitive impairment (MCI) and dementia in women, as reported in a study.

It remains uncertain whether morning or bedtime dosing of antihypertensive drugs is better than the other in terms of efficacy, but the latter appears to significantly reduce the incidence of myocardial infarction (MI), suggests a study.

Young adults with a faster decline in lung function, as measured by forced vital capacity (FVC) or forced expiratory volume in 1 second (FEV1), are at greater risk of coronary artery calcium (CAC) progression in midlife, as shown in a study.

Treatment with qiliqiangxin (QLQX), a traditional Chinese medicine (TCM), significantly reduces the risk of hospitalization due to heart failure (HF) and cardiovascular (CV) death in patients with HF and reduced ejection fraction (HFrEF), according to the QUEST* trial presented at ESC 2023.

A 12-month treatment course of edoxaban appears to yield superior outcomes for cancer patients with isolated distal deep vein thrombosis (DVT), being associated with reduced incidence of recurrent venous thromboembolism (VTE) or VTE-related deaths as compared with a 3-month treatment course, a study has shown.